Flossing teeth: a surprising link to fewer strokes and migraines

April 20, 2025

You may think of flossing as a way to keep your teeth and gums healthy, but new research shows that it may also protect your heart and brain. Recent scientific studies reveal compelling connections between gum health, stroke risk, and chronic migraines.

A major study led by Dr. Souvik Sen at the University of South Carolina found that flossing at least once a week can cut your risk of ischemic stroke by 22% and cardioembolic stroke by 44%. Flossing also lowers the risk of atrial fibrillation, a heart rhythm problem that raises stroke risk. These benefits are similar to those of aspirin but without the side effects of increased bleeding and stomach ulcers. The reason may be that flossing reduces gum disease and oral inflammation, which are linked to heart and blood vessel problems.

Two recent reviews have highlighted that people with gum disease (periodontitis) are more likely to suffer from migraines. One large observational study found that those with periodontitis had a 29% higher risk of migraines, and the worse the gum disease, the higher the risk. A systematic review of eight studies confirmed this link, pointing to inflammatory markers, like CGRP and PTX3, that are elevated in both conditions. Chronic inflammation from gum disease may trigger or worsen migraine attacks.

Flossing is a simple, affordable way to lower your risk of stroke and potentially reduce migraine frequency. By keeping your gums healthy, you’re also helping to protect your heart and brain.

Answer from Perplexity: pplx.ai/share

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe